* After treatment with PCSK9 inhibitors, plasma from FH patients showed altered cholesterol distribution, with less cholesterol in LDL and more in HDL.
* PCSK9 inhibitors enhanced the movement of cholesterol to feces in specific mouse models and support the reverse cholesterol transport pathway in patients with heterozygous FH.